Outcomes of intensity-modulated radiation therapy for intermediate- or high-risk prostate cancer: a single-institutional study
Outcomes of intensity-modulated radiation therapy for intermediate- or high-risk prostate cancer: a single-institutional study
复制标题
DOI：
10.1093/jjco/hyab167
复制
发表时间：
2021-10-23
影响因子：
2.4
通讯作者：
Yoshioka, Yasuo
中科院分区：
文献类型：
--
作者：
Sasamura, Kazuma;Soyano, Takashi;Yoshioka, Yasuo
背景日本关于调强放射治疗局限性前列腺癌的结果报道很少。本研究旨在评估调强放疗对中高危前列腺癌患者的疗效和毒性。方法我们对从我们的机构数据库中检索的数据进行了回顾，这些数据来自接受过局部前列腺癌调强放射治疗的患者，放射剂量为78戈伊，分39次。分析了201例中危前列腺癌和311例高危前列腺癌患者的资料。结果调强适形放射治疗完成后中位随访时间为100个月（范围，24-154）。中危组5年生存率、总生存率、无转移生存率和无生化复发生存率分别为99%、95%、95%和94%，8年分别为99%、91%、90%和86%;高危患者5年时的相应比率分别为100、97、91和84%，8年时分别为96、92、84和76%。晚期2-3级泌尿生殖系统毒性的粗发生率为28.1%，晚期3级泌尿生殖系统毒性的粗发生率为2.0%。晚期2级胃肠道毒性的粗发生率为5.1%，无晚期3级胃肠道毒性病例。结论调强适形放射治疗对局限性中高危前列腺癌有较好的疗效，且毒副反应小，本研究评价了512例局限性前列腺癌调强适形放射治疗的疗效和毒副反应，临床疗效满意。
Background There are few reports from Japan about the outcomes of intensity-modulated radiation therapy for localized prostate cancer. This study was aimed at assessing the efficacy and toxicity of intensity-modulated radiation therapy in patients with intermediate- or high-risk prostate cancer. Methods We conducted a review of the data, retrieved from our institutional database, of patients who had received intensity-modulated radiation therapy for localized prostate cancer at a radiation dose of 78 Gy in 39 fractions. Data of 201 patients with intermediate-risk prostate cancer and 311 patients with high-risk prostate cancer were analyzed. Results The median follow-up period after the completion of intensity-modulated radiation therapy was 100 months (range, 24-154). The rates of cause-specific survival, overall survival, metastasis-free survival and biochemical recurrence-free survival in the intermediate-risk patients were 99, 95, 95 and 94% at 5 years and 99, 91, 90 and 86% at 8 years, respectively; the corresponding rates in the high-risk patients were 100, 97, 91 and 84% at 5 years and 96, 92, 84 and 76% at 8 years, respectively. The crude incidence of late grade 2-3 genitourinary toxicity was 28.1%, and that of late grade 3 genitourinary toxicity was 2.0%. The crude incidence of late grade 2 gastrointestinal toxicity was 5.1%, and there were no cases of late grade 3 gastrointestinal toxicity. Conclusions Our data demonstrated that intensity-modulated radiation therapy is effective for patients with localized intermediate-risk or high-risk prostate cancer while having minimal toxicity.This study evaluated the efficacy and toxicity of IMRT in 512 patients with locaized prostate cancer, and we demonstrated that clinical outcomes were satisfactory.